Informed consent was obtained after the nature of the procedures (blood drawing, measures of coagulation and medical history) had been fully explained. The procedures followed were in accordance with the ethical standards of the institutional review board of the Jewish Hospital (OH, USA), which approved the research protocol.
We have recently described deep venous thrombosis [1] , pulmonary embolism, amaurosis fugax and osteonecrosis (ON) of the hips after exogenous testosterone (T) was given to six previously healthy men with no ante cedent thrombosis, five of whom were found to have previously undiagnosed factor V Leiden hetero zygosity and one who had high factor VIII [1] . ON may be caused, in part, by thrombophilia and hypofibrinolysis-induced thrombus of the major efferent veins of the head of the femur leading to increased intracortical pressure and reduced arterial inflow, with subsequent bone hypoxia and bone death [1, 2] .
The major source of estradiol (E2) in men comes from the aromatization of T (endogenous or exogenous) to E2 [3] . We speculated [1] that when exogenous T is aromatized to E2 [3] [4] [5] [6] , and E2-induced thrombophilia is superimposed on underlying familial thrombophilia, thrombosis occurs [1] . Estrogen use in postmenopausal women is associated with increased risk of venous thrombosis [7, 8] and ischemic stroke [9] . We have recently reported two previously healthy women who developed ON [10] and central retinal vein occlusion thrombosis (CRVO) [8] after starting T therapy for libido (patch 300 µg and T-E2 (TE) pellet [75-75 mg]) and were found to have previously undiagnosed familial thrombophilia (high homocysteine and high factor XI, respectively).
In postmenopausal women and in women with surgical oophorectomy, the roles played by androgens or estrogens in women's libido remain Thrombosis in three postmenopausal women receiving testosterone therapy for low libido Charles J Glueck* 1 , Dedrick Bowe 1,2 , Alejandro Valdez 1,2 & Ping Wang 1 Our hypothesis was that thrombosis occurring in postmenopausal women given testosterone (T) or testosterone-estradiol (TE) to improve libido was associated with a prothrombotic interaction between T or TE with underlying inherited procoagulants. In three previously healthy, postmenopausal, Caucasian women with no antecedent thrombosis and previously undiagnosed G20210A prothrombin gene heterozygosity, hyperhomocysteinemia and 4G4G homozygosity of the PAI-1 gene, we describe central retinal vein thrombosis and osteonecrosis that developed at 16 days, 2 months and 11 months in the three cases, respectively, after T or TE therapy was started. Exogenous T or TE in postmenopausal women may be associated with thrombosis, speculatively when it is superimposed on underlying procoagulants. This small observational case series can serve as a starting point for a larger observational study with greater detail on patient history, serum T and estradiol levels, and detailed PCR and serologic assessment of thrombophilia and hypofibrinolysis. 1 In the sequential order of their referral for evaluation of CRVO or ON, patient information was obtained by history and physical examination. Some of the data for one of the three women in the current report (case one) (TaBle 1) are also included in another paper [10] . None of the data for the other two women have been previously reported [1, 8, 19] .
After an overnight fast, blood was drawn in the seated position for assessment of t hrombophilia and hypofibrinolysis [20] .
Laboratory assessment of coagulation factors PCR assays
PCR measures of G1691A factor V Leiden, G20210A prothrombin, MTHFR C677T-A1298C and 4G5G plasminogen activator inhibitor activity (PAI-1) mutations were performed in all cases using previously published methods by laboratory staff who were blinded to the subjects' status ( diagnosis and severity of disease) [21] [22] [23] .
Serologic measures
Serologic measures included anticardiolipin antibodies (IgG and IgM), antigenic protein C, total and free antigenic protein S, antigenic antithrombin III, resistance to activated protein C (RAPC), activated partial thrombo plastin time (APTT), lupus anticoagulant, factors VIII, factor XI and homocysteine. Established, previously published methods were used [21, 24] . Serologic measures of Lp(a) and plasminogen activator inhibitor activity were carried out using e stablished, previously published methods [22, 25] .
Results
Interaction of T-supplementation therapy in postmenopausal women with previously un diagnosed procoagulants led to thrombotic events, including CRVO thrombosis and ON.
The temporal associations of exogenous T or TE with subsequent, otherwise unprovoked, thrombotic events, led us to evaluate for underlying previously undiagnosed procoagulants in three postmenopausal women (TaBle 1) .
Before our evaluation, which was triggered by thrombotic events, none of the previously healthy women had a history of thrombosis and none had any previous coagulation testing. They had no antecedent history of trauma, surgery, overt cancer or immobilization. None of the three women had taken long-term, highdose corticosteroids, none were alcoholic and all three were nonsmokers. Cases one and two were naturally postmenopausal, and case three was After their thrombotic events on T or TE therapy given to improve libido, one woman (case three) was found to be heterozygous for the G20210A prothrombin gene mutation, one woman (case two) had hyperhomocysteinemia with accompanying MTHFR C677T-A1298C compound heterozygosity and PAI-1 gene 4G4G homozygosity, and one woman (case one) had PAI-1 4G4G homozygosity (TaBle 1) .
Case one
To improve libido, this 53-year-old postmenopausal Caucasian woman was given a T patch that delivered 300 µg/day. Bilateral hip ON was diagnosed by MRI and x-ray 11 months after starting T. Coagulation tests revealed 4G4G homozygosity of the PAI-1 gene (TaBle 1) .
Case two
To improve libido, this 54-year-old postmenopausal Caucasian woman was given a T-E (75-75 mg) subcutaneous implant, and 16 days after the implant, she developed CRVO. Coagulation tests revealed compound hetero zygosity for the MTHFR C677T and A1298C mutations, with accompanying thrombophilic high homocysteine, as well as 4G4G homozygosity of the PAI-1 gene (TaBle 1) .
Case three
To improve libido, this 45-year-old Caucasian woman, 8 years after oophorectomy, was given a T-E (75-75 mg) subcutaneous implant. Bilateral hip pain occured 1 month later; 2 months after the implant, bilateral ON of both hips was diagnosed by x-ray and MRI. Coagulation studies revealed thrombophilic heterozygosity for the G20210A mutation of the prothrombin gene (TaBle 1) .
When taking the TE subcutaneous implant, serum T in case three was high (76 ng/dl) and E2 was high (260 pg/ml) for a postmenopausal woman (TaBle 2) . A total of 3 weeks after stopping the T-E2 implant, T fell to a very low level (<3 ng/dl), and E2 fell into the normal p ostmenopausal range (31.1 pg/ml) (TaBle 2) .
Discussion
The novel finding of the current study was that in three previously healthy postmenopausal women without previous thrombotic events, and without previously known prothrombotic factors, thrombotic events (CRVO and ON) occurred at 16 days, 2 months and 11 months in the three cases, respectively, after T or TE were given to improve libido. The data of the current study confirms and expands the association between thrombosis and T treatment in our initial report on six men [1] , our second report on 13 men and one woman [19] , and our third report in one woman with CRVO [8] . Congruent with our previous reports, which were predominantly in men (19 out of 21 cases) [1, 8, 19] , the thrombotic events in the three women of the current study were associated with previously undiagnosed heterozygosity for the G20210A prothrombin gene mutation, MTHFR C677T and A1298C compound heterozygosity with accompanying high homocysteine, and with the 4G4G mutation of the PAI-1 gene. High homocysteine is a risk factor for CRVO [8] . ON is associated with the G20210A prothrombin gene mutation [26] and with the 4G4G mutation of the PAI-1 gene [2, 27, 28] . Given an estimated population prevalence of heterozygosity for the factor V Leiden mutation in 5% of women, [29] and prevalence of thrombophilias (factor V Leiden, prothrombin, MTHFR mutations, high homocysteine, and high factors VIII and XI) in 18-28% of women [7, 30, 31] , there is considerable opportunity for women given T or TE to also have an increased likelihood of thrombosis. We speculate that the increasing and offlabel frequency of T prescription to improve women's libido may be associated with a parallel and largely preventable increase in thrombotic events [1, 8, 19] and, possibly, cardiovascular adverse events [32] .
We speculate that as exogenous T is aromatized to E2 [1, 33] , thrombophilic E2 interacts with previously undiagnosed procoagulants, such as high homocysteine and the G20210A prothrombin mutation, to produce thrombotic events, as in the current study, and in our recent reports in men [1] and in both men and women [8, 19] who were receiving T. As recently reported in women, given a 100-mg T implant for symptoms of androgen deficiency [34] , 4 weeks after implantation and when androgen deficiency symptoms returned later, serum T levels were several-fold higher than endogenous T. Glaser et al. concluded that "pharmacologic dosing of subcutaneous T, as evidenced by serum levels on therapy, is needed to produce a physiologic effect in female patients" [34] . Congruent with this report by Glaser et al., in one woman in our current study where T and E2 were measured on and off TE therapy, T and E2 were both high on TE (76 ng/dl and 260 pg/ml, respectively), and off TE, T fell to very low levels (<3 ng/dl) and E2 fell to normal post menopausal levels (31.1 pg/ml) [34] . We speculate that in women given 75-100-mg T pellet implantation, as in two women in the current report, supraphysiologic serum T will be aromatized to supraphysiologic high E2 [34] , increasing the risk of thrombosis in women with underlying, and previously undiagnosed, thrombophilia [1, 8, 19] . When 75-mg T is combined with 75-mg E2, as in two women in the current study, we speculate that thrombophilic high serum E2 levels may be even more supraphysiologic.
As reported by Svartborg et al., in age-adjusted analyses, endogenous sex hormone levels in men are not associated with risk of venous thromboembolism [35] . In our previous report of 13 men and one woman with thrombotic events after T therapy [19] , endo genous male sex hormones were not associated with venous thromboembolism. Endogenous E2 in women is not related to thrombophilic resistance to activated protein C [36] . However, there are case reports of deep vein thrombosis pulmonary embolus in men after exogenous testosterone-nandrolone [37] , and cerebral sinus thrombosis after exogenous nandrolone [38] . Exogenous androgenic hormone regimens increase risk of breast cancer in women [39] ; however, to the best of our knowledge, the current report and our two other recent studies are the first to document thrombotic events associated with T or TE therapy in women [8, 19] .
Conclusion
Exogenous T or TE therapy in postmenopausal women may be associated with thrombosis, speculatively when it is superimposed on underlying thrombophilia, such as hyperhomo cysteinemia and G20210A prothrombin gene hetero zygosity, as in the current report. Our small observational case series can serve as a starting point for a larger observational study with greater detail on patient history, serum T and E2 levels, and detailed PCR and serologic assessment of thrombophilia and hypofibrinolysis.
Future perspective
In 5-10 years, the cost of serologic and PCR measures of major mutations that promote thrombosis should fall sharply, thus allowing economically feasible screening of women for procoagulants before prescription of exogenous T or TE. This will facilitate better assessment of benefit-to-risk ratios relative to T and TE treatment in women.
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Executive summary
• The novel finding of the current study was that in three previously healthy postmenopausal woman without previous thrombotic events, and without previously known procoagulants, thrombotic events (central retinal vein occlusion and osteonecrosis) occurred at 16 days, 2 months and 11 months, in the three cases respectively, after testosterone or testosterone-estradiol therapy. • Our small observational case series can serve as a starting point for a larger observational study with greater detail on patient history, serum testosterone and estradiol levels, and detailed PCR and serologic assessment of thrombophilia and hypofibrinolysis. casE sEriEs -Glueck, Bowe, Valdez & Wang
